Lerochol (Lerodalcibep-liga) is a medicine that treats what
Lerochol (Lerodalcibep-liga) is a proprotein convertase subtilisin kexin type (PCSK9) inhibitor primarily used to treat hypercholesterolemia in adults. As an adjunct to diet and exercise, Lerochol can significantly reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with high cholesterol, including heterozygous familial hypercholesterolemia (HeFH). Research shows that lowering LDL-C levels in patients with high cholesterol is important for improving the prognosis of patients at risk of cardiovascular disease.

The main component of Lerochol is lerodalcibep-liga, a recombinant fusion protein that binds and inhibits PCSK9. Its mechanism of action is by inhibiting the binding of PCSK9 to low-density lipoprotein receptor (LDLR) on the surface of liver cells, thereby preventing the degradation of LDLR in the liver. In this way, Lerochol increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels.
As a third-generation PCSK9 inhibitorLerochol is easy to use, requiring only a small-volume subcutaneous injection once a month, and its room temperature stability can be extended to three months. This feature allows patients to be more flexible when taking medications and reduces the trouble of frequent injections.
In clinical application,Lerochol is administered by subcutaneous injection once a month. According to clinical trial data, common adverse reactions in patients treated with Lerochol include injection site reactions, nasopharyngitis, diarrhea, nausea and peripheral edema, with the incidence rate of these adverse reactions exceeding 1%.
In short,Lerochol, as a new PCSK9 inhibitor, provides an effective treatment option for patients with hypercholesterolemia. It helps improve the risk of cardiovascular disease by reducing LDL-C levels and shows good clinical application prospects. With in-depth research on its mechanism of action and clinical effects, it is believed that this drug will play an increasingly important role in cardiovascular health management.
Reference materials:https://www.drugs.com/history/lerochol.html
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)